Abstract
This review provides a molecular perspective of partial agonism at the A1 adenosine receptor. The structure-activity relationships (SAR) for affinity and intrinsic efficacy of analogues of the full agonist N6-cyclopentyladenosine (CPA) are emphasized. Both general models of activation of G protein-coupled receptors and specific molecular models of the A1-adenosine receptor are used to interpret the results of efforts to synthesize and assay effects of partial agonists. The SAR of affinity and intrinsic efficacy of the 2 ’ , 3 ’ , and especially the 5 ’ -deoxy derivatives of CPA is presented. From this analysis, the nature of the interactions of specific atoms and substituents of the CPA molecule with the A1-adenosine receptor are deduced and presented pictorially. As an example of the therapeutic potential of partial agonists, the design and testing of analogues of CPA to provide chronic ventricular rate control during atrial fibrillation is described. The challenges associated with designing a partial A1-adenosine receptor agonist for providing chronic ventricular rate control during atrial fibrillation are many. To meet these challenges, further medicinal chemistry efforts in the area of partial A1- adenosine receptor agonism are still needed.
Keywords: adenosine, partial, agonist, adenosine a1 receptor, structure activity relationship
Current Topics in Medicinal Chemistry
Title: Partial A1 Adenosine Receptor Agonists from a Molecular Perspective and Their Potential Use as Chronic Ventricular Rate Control Agents During Atrial Fibrillation (AF)
Volume: 4 Issue: 8
Author(s): Jeff A. Zablocki, Lin Wu, John Shryock and Luiz Belardinelli
Affiliation:
Keywords: adenosine, partial, agonist, adenosine a1 receptor, structure activity relationship
Abstract: This review provides a molecular perspective of partial agonism at the A1 adenosine receptor. The structure-activity relationships (SAR) for affinity and intrinsic efficacy of analogues of the full agonist N6-cyclopentyladenosine (CPA) are emphasized. Both general models of activation of G protein-coupled receptors and specific molecular models of the A1-adenosine receptor are used to interpret the results of efforts to synthesize and assay effects of partial agonists. The SAR of affinity and intrinsic efficacy of the 2 ’ , 3 ’ , and especially the 5 ’ -deoxy derivatives of CPA is presented. From this analysis, the nature of the interactions of specific atoms and substituents of the CPA molecule with the A1-adenosine receptor are deduced and presented pictorially. As an example of the therapeutic potential of partial agonists, the design and testing of analogues of CPA to provide chronic ventricular rate control during atrial fibrillation is described. The challenges associated with designing a partial A1-adenosine receptor agonist for providing chronic ventricular rate control during atrial fibrillation are many. To meet these challenges, further medicinal chemistry efforts in the area of partial A1- adenosine receptor agonism are still needed.
Export Options
About this article
Cite this article as:
Zablocki A. Jeff, Wu Lin, Shryock John and Belardinelli Luiz, Partial A1 Adenosine Receptor Agonists from a Molecular Perspective and Their Potential Use as Chronic Ventricular Rate Control Agents During Atrial Fibrillation (AF), Current Topics in Medicinal Chemistry 2004; 4 (8) . https://dx.doi.org/10.2174/1568026043450998
DOI https://dx.doi.org/10.2174/1568026043450998 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Opioids: Old Drugs for Potential New Applications
Current Pharmaceutical Design Anticancer Actions of Omega-3 Fatty Acids - Current State and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Withdrawal Notice: Renoprotective Effect of Curcumin Labelled on Mesoscale Nanoparticles (MNPs) in Renal Ischemia-Reperfusion Injury (RIRI) via the miR-146a/nNOS/NO/cGMP/PKG Signaling Pathway
Current Pharmaceutical Biotechnology Ozone: A Multifaceted Molecule with Unexpected Therapeutic Activity
Current Medicinal Chemistry Editorial (Thematic Issue: Modifying Cardiovascular Risk Factors: Current Opinion and Future Trends)
Current Pharmaceutical Design Thioredoxin-1 is a Novel and Attractive Therapeutic Approach for Various Diseases Including Cardiovascular Disorders
Cardiovascular & Hematological Disorders-Drug Targets The Cannabinoids Switch of Oxidative Stress: A Double-Edged Sword
Mini-Reviews in Organic Chemistry Soybean and Processed Soy Foods Ingredients, and Their Role in Cardiometabolic Risk Prevention
Recent Patents on Food, Nutrition & Agriculture Therapeutic Approaches to Modulating Glutathione Levels as a Pharmacological Strategy in Alzheimer`s Disease
Current Alzheimer Research Opioid-induced Cardioprotection
Current Pharmaceutical Design From Preclinical to Clinical Trials: An Update on Potential Therapies for Huntington’s Disease
Current Psychopharmacology Artificial Blood: A Futuristic Dimension of Modern Day Transfusion Sciences
Cardiovascular & Hematological Agents in Medicinal Chemistry Cardiac Imaging in Heart Failure with Comorbidities
Current Cardiology Reviews Human Tissue Kallikrein: A New Bullet for the Treatment of Ischemia
Current Pharmaceutical Design Ventilation During Pediatric CPR
Current Pediatric Reviews Glycine/NMDA Receptor Antagonists as Potential CNS Therapeutic Agents: ACEA-1021 and Related Compounds
Current Topics in Medicinal Chemistry A Review of Oxidative Stress Related Genes and New Antioxidant Therapy in Diabetic Nephropathy
Cardiovascular & Hematological Agents in Medicinal Chemistry Impact of HbA1C (Glycated Hemoglobin) and Glucose on Outcomes of Mechanical Thrombectomy in Patients with Large Artery Occlusion
Current Neurovascular Research The Role of Oxidative Stress in Depressive Disorders
Current Pharmaceutical Design Cardiovascular Effects of the Phytoestrogen Genistein
Current Medicinal Chemistry - Cardiovascular & Hematological Agents